Referencias
Gruen ME, Myers JAE, Tena J-KS,Becskei C, Cleaver DM, Lascelles BDX. Frunevetmab, afelinized anti-nerve growth factor monoclonal antibody, forthe treatment of pain from osteoarthritis in cats. J Vet InternMed. 2021;35(6):2752-2762. doi:10.1111/jvim.162912762 GRUEN ET AL.
Gruen, M. E., Myers, J. A. E., & Lascelles, B. D. X. (2021). Efficacy and safety of an anti-nerve growth factor antibody (Frunevetmab) for the treatment of degenerative joint disease-associated chronic pain in cats: A multisite pilot field study. Frontiers in Veterinary Science, 8, 610028. DOI: 10.3389/fvets.2021.610028.
Walters, R. R., Boucher, J. F., & De Toni, F. (2021). Pharmacokinetics and immunogenicity of frunevetmab in osteoarthritic cats following intravenous and subcutaneous administration. Frontiers in Veterinary Science, 8, Article 687448. DOI: 10.3389/fvets.2021.687448.
Reid J, Gildea E, Davies V, Thompson J and Scott M (2024) Measuring the effect of the anti-nerve growth factor antibodies bedinvetmab and frunevetmab on quality of life in dogs and cats with osteoarthritis using a validated health-related quality of life outcome measure: an observational real-world study. Front. Vet. Sci. 11:1395360. doi: 10.3389/fvets.2024.1395360
Es esencial que un Médico Veterinario realice un diagnóstico preciso de la condición subyacente en cada paciente antes de iniciar cualquier tratamiento con Solensia®. Solensia® (Frunevetmab) Reg. B–1196–410. Uso veterinario. Consulte al Médico Veterinario. Su venta requiere receta médica. Marcas registradas propiedad de Zoetis. Registros propiedad de Zoetis México, S. de R.L. de C.V., Paseo de los Tamarindos No. 60 Planta Baja, Col. Bosques de las Lomas, Alcaldía de Cuajimalpa, México, Ciudad de México, C.P. 05120. ©2026. MM–44904.